What this is
- How it works
- How it works isn't classified yet
- Tested for
- Atopic Dermatitis (AD), Psoriasis (PsO), Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
- Main trialPhase 1
- “The goal of this clinical trial is to study the drug LPX-TI641 in patients with atopic dermatitis and psoriasis. We will compare the safety and tolerability of LPX-TI641 to placebo ( a look-alike solution) that contains no drug. We will also evaluate the plasma pharmacokinetics of LPX-TI641. LPX-TI641 (or placebo) will be administered orally for 28 days.”In the company’s words, NCT06982352 on ClinicalTrials.gov
Other drugs for Atopic Dermatitis (AD)
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 15 Jan 2026 | Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis | |
| Phase 1Active, not recruiting | 15 Nov 2026 | Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis | |
| Phase 1Completed | 15 Aug 2024 | First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026